Cardiomagnil pills 75+15.2mg, 100pcs

Composition

1 tab. acetylsalicylic acid 75 mg

magnesium hydroxide 15.2 mg

Auxiliary substances:

corn starch – 9.5 mg,

microcrystalline cellulose-12.5 mg,

magnesium stearate-150 mcg,

potato starch-2.0 mg.

Shell composition:

hypromellose (methylhydroxypropylcellulose 15) – 460 mcg,

propylene glycol-90 mcg,

talc-280 mcg.

Pharmacological action

Cardiomagnil – antiplatelet.

Pharmacodynamics

The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of COX-1, which blocks the synthesis of thromboxane a2 and suppresses platelet aggregation. It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands the scope of its application in various vascular diseases. ASA also has anti-inflammatory, analgesic, and antipyretic effects.

Magnesium hydroxide, which is part of Cardiomagnil®, protects the gastrointestinal mucosa from the effects

of ASA.

ASA is absorbed from the gastrointestinal tract almost completely. T1 / 2 of ASA is about 15 minutes, because with the participation of enzymes, ASA is rapidly hydrolyzed to salicylic acid (SC) in the intestine, liver, and blood plasma. T1 / 2 SC is about 3 hours, but it can significantly increase with simultaneous use of large doses of ASA (more than 3 g) as a result of saturation of enzyme systems.

The bioavailability of ASA is about 70%, but this value largely fluctuates, since ASA undergoes presystemic hydrolysis (gastrointestinal mucosa, liver) into SC under the action of enzymes. The bioavailability of SC is 80-100%.

The doses of magnesium hydroxide used do not affect the bioavailability of acetylsalicylic acid.

Indications

• prevention of recurrent myocardial infarction and blood vessel thrombosis;
• Primary prevention of such cardiovascular diseases as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age);
• unstable angina;
• prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty).

Contraindications

• bleeding in the brain;
• the tendency to bleeding (vitamin K, thrombocytopenia, hemorrhagic diathesis);
• bronchial asthma induced by ingestion of salicylates and NSAIDs;
• erosive-ulcerative lesions of the gastrointestinal tract (in the phase of exacerbation);
• gastrointestinal bleeding;
• renal failure severe (CC<10 ml/min);
• deficiency of glucose-6-phosphate dehydrogenase;
• simultaneous use of methotrexate (>15 mg / week);
• I and III trimester of pregnancy;
• lactation (breastfeeding);
• childhood and adolescence to 18 years;
• hypersensitivity to acetylsalicylic acid, auxiliary substances of the drug and other NSAIDs.

With caution, the drug should be prescribed for gout, hyperuricemia, a history of ulcerative lesions of the gastrointestinal tract or bleeding from the gastrointestinal tract, with renal and/or liver failure, bronchial asthma, hay fever, nasal polyposis, allergic conditions, in the second trimester of pregnancy.

Side effects

The frequency of adverse reactions listed below was determined according to the following: very common (≥1/10); often (> 1/100,1/1000,1/10 000, >

Allergic reactions: often – urticaria, angioedema; sometimes-anaphylactic reactions.

From the digestive system: very often – heartburn; often-nausea, vomiting; sometimes-abdominal pain, ulcers of the gastric and duodenal mucosa, gastrointestinal bleeding; rarely-perforation of the stomach or duodenal ulcer, increased activity of liver enzymes; very rarely-stomatitis, esophagitis, erosive lesions of the upper gastrointestinal tract, strictures, colitis, irritable bowel syndrome.

From the respiratory system: often-bronchospasm.

From the hematopoietic system: very often-increased bleeding; rarely-anemia; very rarely-hypoprothrombinemia, thrombocytopenia, neutropenia, aplastic anemia, eosinophilia, agranulocytosis.

From the central nervous system: sometimes-dizziness, drowsiness; often-headache, insomnia; rarely-tinnitus, intracerebral hemorrhage.

Interaction

When used simultaneously, ASA enhances the effect of the following medications: :

• methotrexate — due to a decrease in renal clearance and its displacement from protein binding;
• heparin and indirect anticoagulants-due to a violation of platelet function and displacement of indirect anticoagulants from protein binding;
• thrombolytic and antiplatelet drugs (ticlopidine);
• digoxin-due to a decrease in its renal excretion;
• hypoglycemic agents (insulin and sulfonylurea derivatives) — due to the hypoglycemic properties of ASA itself in high doses and the displacement of sulfonylurea derivatives from the bond with proteins;
• valproic acid — due to its displacement from the bond with proteins.

An additive effect is observed when ASA is taken simultaneously with ethanol (alcohol).

ASA weakens the effect of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.

By increasing the elimination of salicylates, systemic corticosteroids weaken their effect.

Antacids and colestyramine reduce the absorption of the drug.

How to take, course of use and dosage

Tablets should be swallowed whole, washed down with water. If desired, the tablet can be broken in half, chewed or pre-ground.

For primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age),1 tab is prescribed. Cardiomagnil containing acetylsalicylic acid at a dose of 150 mg on the first day, then 1 tab. Cardiomagnet containing acetylsalicylic acid at a dose of 75 mg 1 time/day.

To prevent repeated myocardial infarction and blood vessel thrombosis,1 tab is prescribed. Cardiomagnet containing acetylsalicylic acid at a dose of 75-150 mg 1 time/day.

To prevent thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty),1 tab is prescribed. Cardiomagnet containing acetylsalicylic acid at a dose of 75-150 mg 1 time/day.

With unstable angina pectoris,1 tab is prescribed. Cardiomagnet containing acetylsalicylic acid at a dose of 75-150 mg 1 time/day.

Overdose

Symptoms of moderate overdose: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.

Treatment: the stomach should be washed, activated charcoal should be prescribed, and symptomatic therapy should be performed.

Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.

Treatment: immediate hospitalization in specialized departments for emergency therapy-gastric lavage, determination of acid-base balance, alkaline and forced alkaline diuresis, hemodialysis, use of saline solutions, activated charcoal, symptomatic therapy.

When performing alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when the concentration of salicylates in plasma is more than 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children.

Special instructions

Take the drug Cardiomagnil should be after the appointment of a doctor.

Acetylsalicylic acid can provoke bronchospasm, as well as cause asthma attacks and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, and allergic reactions (such as skin reactions, pruritus, and urticaria) to other medications.

Acetylsalicylic acid can cause bleeding of varying severity during and after surgery.

A few days before the planned surgical intervention, the risk of bleeding should be evaluated in comparison with the risk of ischemic complications in patients taking low doses of acetylsalicylic acid. If the risk of bleeding is significant, acetylsalicylic acid should be temporarily discontinued.

The combination of acetylsalicylic acid with anticoagulants, thrombolytics and antiplatelet drugs is associated with an increased risk of bleeding.

Taking acetylsalicylic acid in low doses can provoke the development of gout in predisposed individuals (with reduced uric acid excretion).

The combination of acetylsalicylic acid with methotrexate is accompanied by an increased frequency of side effects from the hematopoietic system.

Taking acetylsalicylic acid in high doses has a hypoglycemic effect, which should be borne in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic agents for oral use and insulin.

With the combined use of systemic corticosteroids and salicylates, it should be remembered that during treatment, the concentration of salicylates in the blood is reduced, and after the withdrawal of systemic corticosteroids, an overdose of salicylates is possible.

The combination of acetylsalicylic acid with ibuprofen is not recommended in patients with an increased risk of cardiovascular diseases: when used simultaneously with ibuprofen, there is a decrease in the antiplatelet effect of acetylsalicylic acid in doses up to 300 mg, which leads to a decrease in the cardioprotective effects of acetylsalicylic acid.

Exceeding the dose of acetylsalicylic acid above the recommended therapeutic doses is associated with the risk of gastrointestinal bleeding.

Caution should be exercised in elderly patients with prolonged use of low-dose acetylsalicylic acid as an antiplatelet therapy due to the risk of gastrointestinal bleeding.

When taking acetylsalicylic acid with ethanol at the same time, the risk of damage to the gastrointestinal mucosa and prolongation of bleeding time is increased.

Influence on the ability to drive motor vehicles and manage mechanisms

During treatment with acetylsalicylic acid, patients should exercise caution when driving vehicles and engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Film-coated tablets.

Storage conditions

The drug should be stored in a dry place, protected from light and inaccessible to children at a temperature not exceeding 25°C.

Shelf

life is 5 years.

Active ingredient

: Acetylsalicylic acid, [Magnesium hydroxide]

Dosage form

Tablets

Purpose

Pregnant women only in the second trimester as prescribed by a doctor, Adults as prescribed by a doctor

Indications

Prevention of heart attacks and strokes, Angina pectoris, Heart failure, Prevention of thrombosis